Tezosentan

Tezosentan
(IUPAC) ime
	N-[6-(2-Hidroksietoksi)-5-(2-metoksifenoksi)-2-[2-(2H-tetrazol-5-il)piridin-4-il]pirimidin-4-il]-5-propan-2-ilpiridin-2-sulfonamid
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	151174
ChemSpider	133242
ChEMBL	CHEMBL61780
Hemijski podaci
Formula	C27H27N9O6S
Mol. masa	605,624
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C27H27N9O6S/c1-16(2)18-8-9-22(29-15-18)43(38,39)34-26-23(42-21-7-5-4-6-20(21)40-3)27(41-13-12-37)31-24(30-26)17-10-11-28-19(14-17)25-32-35-36-33-25/h4-11,14-16,37H,12-13H2,1-3H3,(H,30,31,34)(H,32,33,35,36) ; Key: TUYWTLTWNJOZNY-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Tezosentan je neselektivni ET_A u ET_B receptorski antagonist.^[5] On deluje kao vazodilatator i bio je dizajniran za terapiju pacijenata sa akutnom srčanom insuficijencijom. Nedavne studije su međutim pokazale da tezosentan ne poboljšava dispneju niti redukuje rizik od kardiovakularnih problema.^[6]

Reference[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Urbanowicz, W; Sogni, P, Moreau, R, Tazi, K A, Barriere, E, Poirel, O, Martin, A, Guimont, M C, Cazals-Hatem, D, Lebrec, D (2004). „Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats”. Gut (BMJ Publishing Group Ltd & British Society of Gastroenterology) 53 (12): 1844–1849. DOI:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526.
↑ „Tezosentan does not appear to improve symptoms for patients with acute heart failure”. Medical Studies/Trials. news-medical.net. 7-Nov-2007. Pristupljeno 24. 11. 2007.

Spoljašnje veze[uredi | uredi kod]

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[Urbanowicz-5] Urbanowicz, W; Sogni, P, Moreau, R, Tazi, K A, Barriere, E, Poirel, O, Martin, A, Guimont, M C, Cazals-Hatem, D, Lebrec, D (2004). „Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats”. Gut (BMJ Publishing Group Ltd & British Society of Gastroenterology) 53 (12): 1844–1849. DOI:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526.

[news-med-6] „Tezosentan does not appear to improve symptoms for patients with acute heart failure”. Medical Studies/Trials. news-medical.net. 7-Nov-2007. Pristupljeno 24. 11. 2007.

[1]

[2]

[3]

[4]

[5]

[6]

Tezosentan

Reference[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga